LBI-HTA - Publications - Search - Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
134Kb
Abstract

For the 32 prioritisation (August 2017), 10 drugs were filtered out of 366 identified and were sent to
prioritisation. Of these, 5 drugs were ranked as "highly relevant" by the expert panel, 5 as "relevant" and none as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:HSO: 32nd Prioritisation
Deposited on:23 Aug 2017 12:46
Last Modified:23 Aug 2017 12:46

Repository Staff Only: item control page